SCHEMBL3363276

SCHEMBL3363276

O=C(O)c1cccc(Nc2ccccc2F)c1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 1/20 0.49
KDM4E B2RXH2 2/20 0.46
MAPK8 P45983 1/20 0.45
NPC1 O15118 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
RAB9A P51151 2/20 0.44
FABP4 P15090 2/20 0.43
LMNA P02545 2/20 0.43
ALDH1A1 P00352 1/20 0.43
ALB P02768 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
AKR1B10 O60218 1/20 0.42
TRPA1 O75762 1/20 0.42
ABCB11 O95342 1/20 0.42
DHFR P00374 1/20 0.42
MPO P05164 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CHRM1 P11229 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3364058 0.84 FABP4 (0.58) KDM4ESMN1; SMN2FABP4LMNAALDH1A1
SCHEMBL3364464 0.83 PBRM1 (0.55) CXCL8KDM4ESMN1; SMN2FABP4LMNA
SCHEMBL3363270 0.81 KDM4E (0.53) CXCL8KDM4EMAPK8NPC1SMN1; SMN2
SCHEMBL7036185 0.80 ALDH1A1 (0.48) KDM4ESMN1; SMN2FABP4LMNAALDH1A1
SCHEMBL4256425 0.80 FABP4 (0.65) CXCL8KDM4EMAPK8FABP4LMNA
SCHEMBL27488099 0.78 ALDH1A1 (0.54) KDM4ESMN1; SMN2ALDH1A1KMT2AAKR1C3
SCHEMBL21758213 0.77 CYP2C19 (0.51) KDM4ENPC1SMN1; SMN2RAB9ALMNA
SCHEMBL28289321 0.75 KDM4E (0.64) CXCL8KDM4EMAPK8NPC1SMN1; SMN2
SCHEMBL4219603 0.73 MEN1 (0.51) CXCL8KDM4EMAPK8NPC1SMN1; SMN2
SCHEMBL28325047 0.72 FABP4 (0.47) FABP4ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144872-A1 New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation BIOLIPOX AB 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144872-A1 New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation LTC4S, LTB4R2, LTB4R CXCL8 867/4885KDM4E 2928/4885MAPK8 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.